Intravenous Smart Pumps During Actual Clinical Use: A Descriptive Comparison of Primary and Secondary Infusion Practices by Giuliano, Karen K. et al.
University of Massachusetts Amherst 
ScholarWorks@UMass Amherst 
College of Nursing Faculty Publication Series College of Nursing 
2021 
Intravenous Smart Pumps During Actual Clinical Use: A 
Descriptive Comparison of Primary and Secondary Infusion 
Practices 











































The Art and Science of Infusion Nursing
128  Copyright © 2021 The Authors. Published by Wolters Kluwer Health, Inc. Journal of Infusion Nursing
on behalf of the Infusion Nurses Society.
 ABSTRACT 
 This descriptive observational study was conducted to increase understanding of medication administration practices 
during actual clinical use between 2 commonly used, different types of intravenous (IV) smart pumps. Compliance 
with manufacturer-recommended setup requirements for both primary and secondary infusions and secondary 
medication administration delay was compared between a head-height differential system and a cassette system. A 
total of 301 medication administration observations were included in this study: 102 (34%) for the linear peristaltic IV 
smart pump (medical–surgical: N  = 51; critical care: N  = 51) and 199 (66%) for the cassette pump (medical–surgical: 
N  = 88; critical care: N  = 111). Results found a 0% compliance for primary line setup and 84% compliance for sec-
ondary line setup and 1 omitted medication due to a closed clamp with the linear peristaltic system. For the cassette 
system, there are no head-height requirements. Two roller clamps were found to be in the closed position on initi-
ation of the secondary infusion, but the clinician was alerted by an alarm, so no medication delays occurred. These 
findings support that the current system requirements for flow rate accuracy using head-height differential systems 
are difficult to achieve consistently at the point of care. There is a need for additional human factor designed tech-
nology to replace manual actions  to improve the process of care for nurses and the safety of care for patients. 
Key words:  IV infusion, IV smart pump, medication error, patient safety, quality improvement 
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With an estimated 90% of hospitalized patients receiving intravenous (IV) medications, IV infu-sion pumps are ubiquitous in health care.1 Although there are different types of infusion 
pumps, large-volume IV smart pumps are the most widely 
used in US acute care hospitals because they can administer 
large amounts of both fluids and medications.2-4 Through 
our experiences as practicing nurses, we know the difficulty 
first hand in trying to juggle multiple patient care tasks while 
simultaneously having to safely administer potent IV medica-
tions with significant potential side effects. The reality of pro-
gramming an IV smart pump is that the delivery of even a sin-
gle dose of medication involves multiple steps and keystrokes, 
each of which introduces a potential opportunity for error. A 
recent study compared some of the differences in IV smart 
pump usability with various brands of IV smart pumps and 
examples of findings were that the time to power on ranged 
from 7.1 to 13.8 seconds, and the number of keystrokes 
required to initiate a primary infusion ranged from 10 to 17.5
IV smart pumps have built-in drug libraries, interchange-
ably referred to as a dose error reduction system or dose 
error reduction software (DERS), which are intended to 
reduce medication administration errors. These errors are 
mitigated by drug-associated DERS programming limits, 
which provide various alerts to users if the programmed dose 
is outside of the acceptable range. Soft dosing limits provide 
a warning that the dose may be out of the acceptable range, 
but this limit can be bypassed by the user. When hard-dos-
ing limit alerts are triggered, the IV smart pump must be 
reprogrammed to a different dose before the IV medication 
administration can proceed. While data support that the use 
of IV smart pumps has been associated with reductions in 
medication administration errors, they have not eliminated 
errors, including serious adverse drug events with high-alert 
medications.6-12 High-alert medications are defined by the 
Institute for Safe Medication Practices (ISMP) as medications 
that bear a heightened risk of significant patient harm when 
used in error.13 In our previous research, we found the major-
ity of IV smart pump alerts were bypassed by clinicians at the 
point of care, regardless of whether the medication was high 
alert or non-high alert, a symptom of alert fatigue and a clear 
limitation of IV smart pump safety features.14,15 Considering 
the frequency and importance of IV medication adminis-
tration in acute care, it is noteworthy that few studies have 
investigated the root causes of these serious adverse drug 
events and whether differences in medication administration 
errors exist among different IV smart pump types.
Of the work that has been done, weight-based infusions, 
secondary infusions, and IV boluses have been identified as 
particularly high risk and error prone.2,16 These IV medication 
administration tasks place additional cognitive demands 
on users, are not well standardized within hospital proto-
cols, vary among IV smart pump user interfaces, and have 
associated failure modes that are not easily detected.16 
Unfortunately, available data comparing the workflow and 
usability for the user interfaces of different IV smart pump 
types are scarce.3,16,17 As a result, limited empiric data exist 
about what can and should be required by manufacturers to 
help make their products safer and easier to use.
SECONDARY MEDICATION 
ADMINISTRATION
Secondary medication infusion by large-volume IV smart pump 
is used extensively in US acute care for administering IV medi-
cations ordered for one-time or intermittent dosing. Secondary 
administration is designed to allow the primary continuous infu-
sion to pause during the secondary infusion and then resume 
automatically after the secondary infusion is complete.16-18
In US acute care, anti-infectives and electrolyte replace-
ment for adult patients are commonly delivered by sec-
ondary infusion. Secondary medications are often time 
sensitive, and the following are examples of potentially 
serious clinical consequences that can result from second-








as magnesium or potassium replacement, numerous seri-
ous consequences, including cardiac arrest, are possible.
HEAD-HEIGHT DIFFERENTIAL SYSTEM
Secondary medication administration using a head-height 
differential system requires a head-height differential 
between the primary and secondary fluid containers and 
a primary line back-check valve. Head-height differential 
refers to the difference between the top of the fluid level 
in the primary and secondary fluid containers. With a US 
market share of >50%, the Becton Dickinson (BD) Alaris 
Pump (Becton, Dickinson and Company, Franklin Lakes, NJ) 
is the most common large-volume IV smart pump using this 
technique.4,22 The setup requirements are described below 
and also shown in Figure 1.23
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1. The	IV	smart	pump	is	placed	on	the	IV	pole	in	a	position	that	
is	level	with	the	patient’s	heart,	and	the	top	of	the	fluid	in	the	
primary container is 20 inches above the top of the pump.23
2. A	head-height	differential	of	at	least	9.5	inches	between	




adequate	 infusion.	 These	 head-height	 differentials	 are	
achieved by lowering the primary with a hanger and are 
necessary	to	create	the	hydrostatic	pressure	differential	
required	for	secondary	medications	to	infuse.
3. If the secondary container is >50	or	100	mL	or	the	flow	
rate is high, it is recommended to check the primary con-
tainer	for	flow	and,	if	necessary,	add	a	second	hanger	to	
further lower the primary container.
4. The	 hydrostatic	 pressure	 differential	 closes	 a	 back-check	
valve in the primary tubing, which is required to prevent unin-
tended	primary	flow	or	reverse	flow	from	the	secondary	con-
tainer	into	the	primary	container	instead	of	into	the	patient.
5. The roller clamp on the secondary tubing should be open 
during secondary infusion and closed during the prima-
ry infusion. If the roller clamp is inadvertently closed 
during secondary infusion, no pump alarm will sound, 
and	the	fluid	will	be	pulled	from	the	primary	bag	at	the	
programmed	secondary	flow	rate.
Because the medication administration process using 
linear peristaltic pumps has so many manual setup require-
ments, secondary infusions in particular are prone to 
user errors.2,16,17 If setup specifications are not adhered 
to during clinical use, the secondary medication may not 
infuse at all, may infuse into the primary bag instead of the 
patient, or may infuse concurrently into the patient with 
the primary at a different rate than intended. Furthermore, 
all reported flow rate accuracy testing results (±5%) pro-
vided with the product labeling and included in regulatory 
submissions	 are	 obtained	 using	 the	manufacturer’s	 setup	
specifications. Data support that deviations from manufac-
turer recommendations decrease both flow rate and flow 
rate accuracy.16,17,24
Three specific secondary infusion setup errors that have 
been found to occur include:1,2,16,17,25
1. The use of tubing without a primary line back-check 
valve,	which	can	cause	backflow	into	the	primary	bag	in-
stead	of	directly	into	the	patient.
2. Back-check valve failure because of inadequate head-
height	differentials,	high	secondary	flow	rates,	and	par-
tial	opening	of	needle-free	connectors.	All	of	these	con-
ditions	may	 lead	 to	unintended	flow	 from	 the	primary	
container	 or	 backflow	 into	 the	 primary	 bag	 instead	 of	
directly	into	the	patient.
3. Leaving the roller clamp closed, which prevents the sec-
ondary	medication	from	infusing	at	all.
Following is an example from the US Food and Drug 
Administration (FDA) Manufacturer and User Facility Device 
Experience database, which provides an example of back-
check valve failure.
“The patient was to receive IV albumin piggybacked onto a 
normal saline infusion through an infusion pump. The nurse 
set up the infusion. When she checked in on the patient 
approximately 20 minutes later, she noted that the bottom 
of the saline bag had discolored to amber brown, indicating 
that the albumin was emptying out of the piggybacked bag 
and flowing into the primary bag. The piggybacked infusion 
had been set up correctly, with the secondary bag hung 
higher than the primary bag. The back-check valve in the 
primary tubing should have prohibited flow of the second-
ary infusion into the primary bag.”26
In this case, the backflow into the primary was detect-
able because of the discoloration. However, secondary 
medication backflow due to back-check valve failure is 
generally not detectable. Additionally, once the primary 
infusion resumes, the rate of delivery of the secondary 
medication (which is now actually in the primary bag and 
not in the patient) is determined by the programmed pri-
mary rate.
Lack of secondary medication delivery due to an inad-
vertently closed clamp is often not detected until the 
next dose is due. Both of these errors result in either a 
medication administration delay or a completely missed 
dose.2,16,17
Figure 1 Required components for secondary medication infusion 
using the head-height differential method. Figure used with permis-
sion from Karen K. Giuliano, PhD, RN.
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CASSETTE SYSTEM
Primary and secondary medication administration using a 
cassette system is regulated by valves in the cassette. These 
cassette valves eliminate the need for head-height differen-
tials and a primary line back-check valve for secondary med-
ication administration. Because the secondary medication 
has its own fluid path, if the roller clamp is inadvertently 
engaged during secondary medication administration, an 
alarm will provide notification to the clinician. Thus, cassette 
systems provide a technical mitigation for the 3 reasons 
identified above for secondary medication administration 
error that exist on the head-height differential systems.27
OBJECTIVE
Concerning secondary medication administration, this need 
has already been recognized by ISMP in their recent guide-
lines for optimizing IV smart pumps safely, where they recom-
mend the use of systems for secondary medication infusion 
that do not require a head-height differential.13 The objec-
tive of this study was to measure the impact of medication 
administration practices between 2 types of IV smart pumps 
during actual clinical use. The BD/Alaris pump was used as 
the representative head-height differential system and the 
ICU Medical Plum 360 (ICU Medical, Inc., San Clemente, CA) 
was used as the representative cassette system.
RESEARCH AIMS AND HYPOTHESES
Aim 1
What is the adherence with the requirement of pump–pri-
mary IV head-height differential of 20 inches for the head-
height differential system during actual clinical use?
Because of the complex setup requirements and limited 
physical space during actual clinical use, we hypothesized 
that the pump–primary IV head-height differential for 
appropriate medication administration will be insufficient 
at least 50% of the time during actual clinical use.
Aim 2
What is the adherence with the 9.5-inches secondary 
head-height requirement with the head-height differential 
system pump during actual clinical use?
We hypothesized that the required primary–secondary 
head-height differential for appropriate medication admin-
istration will be insufficient at least 20% of the time during 
actual clinical use.
Aim 3
Is there a difference in secondary medication administra-
tion delay between the head-height differential system and 
cassette system during actual clinical use?
Because of the requirements for a primary line back-check 
valve and the need to manually open the roller clamp 
during secondary infusion with linear peristaltic technolo-
gy, we hypothesized that there would be fewer secondary 
medication administration delays with the cassette system 
as compared with the head-height differential system.
STUDY DESIGN AND METHODOLOGY
Setting
The study design was observational and noninterventional. 
Two large (600- and 800-bed) urban hospitals were used as 
study sites, one that used the head-height differential sys-
tem and one that used the cassette system. Observational 
data collection occurred in both the critical care and 
general medical–surgical clinical units in both study sites. 
Institutional review board approval was obtained at each 
site before beginning data collection, and data were collect-
ed at each site by a single observer.
Sample
Using a point prevalence methodology, data were collected 
on a minimum of 100 medication observations at each site 
(50 in medical–surgical and 50 critical care), which occurred 
over a consecutive 2-day period. Observations using con-
venience sampling were recorded real-time using a case 
report form (CRF).
Inclusion Criteria
All adult patients (18 years or older) hospitalized in either 
a medical–surgical or critical care unit and who had at least 
1 active IV secondary medication order were eligible for 
inclusion in the study.
Exclusion Criteria
Adult patients on the study units who did not have at least 
1 active IV secondary medication order were excluded.
Procedures
1.	 Data	collection	was	completed	on	2	consecutive	week-
days between the hours of 6:00 am and midnight to cap-
ture	medication	administration	at	 various	times	during	
the 24-hour cycle.
2.	 First,	 the	 individual	 site	 investigators	 at	 each	 site	 re-
viewed	 all	 current	 secondary	medication	 orders	 in	 the	
electronic	health	record	(EHR)	for	patients	on	the	critical	






a. Measuring the distance between the top of the IV 
smart	pump	and	the	primary	fluid	level	(which	should	
be 20 inches)
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6.	 Patient	 identification	 was	 confirmed	 for	 all	 observa-
tions	 only	 to	 verify	 the	 EHR	 medication	 orders,	 but	
no	protected	health	information	was	collected	on	the	
CRF.
7.	 Each	 secondary	medication	observation	was	 assigned	
a study number, as this was considered as the unit of 
analysis.
8.	 Using	 the	 ISMP	guidance,	medications	were	 recorded	
as	given	on	time	(±30	minutes	from	order	time)	or	de-
layed (administered outside of the ±30-minute	 time	
window).28





A total of 301 medication administration observations 
were included in this study: 102 (34%) for the head-height 
differential system (medical–surgical: N = 51; critical care: 
N = 51) and 199 (66%) for the cassette system (medical–
surgical: N = 88; critical care: N = 111). Table 1 summarizes 
the descriptive data for secondary bag volume, infusion 
duration, and medication type.
Aim 1
What is the adherence with the requirement of pump–
primary IV head-height differential of 20 inches for the 
head-height differential system during actual clinical use? 
Tables 2 and 3 summarize the total and clinical unit-specific 
data on the measured pump–primary IV head-height differ-
entials, including 5 instances where the primary fluid level 
TABLE 1
Summarized Frequency Data for Secondary Bag Volume, Infusion 
Duration, and Medication Type by Therapeutic Class
Secondary bag volume (mL)
Total Head-height differential system Cassette system
N % N % N %
50 70 23.0% 29 28.4% 41 20.6%
100 182 60.0% 57 55.9% 125 62.8%
150 6 2.0% 0 0.0% 6 3.0%
250 39 13.0% 15 14.7% 24 12.1%
400 1 0.3% 1 1.0% 0 0.0%
500 3 1.0% 0 0.0% 3 1.5%
Secondary infusion duration (min) N % N % N %
15 3 1.0% 3 2.9% 0 0.0%
30 152 50.0% 36 35.3% 116 58.3%
60 79 26.0% 19 18.6% 60 30.2%
90 24 8.0% 9 1.0% 15 7.7%
120 8 3.0% 1 1.0% 7 3.5%
180 4 1.0% 3 0.2% 1 0.0%
240 31 10.0% 31 30.4% 0 0.0%
Medication therapeutic class N % N % N %
Antibiotic 216 72.0% 81 79.4% 135 67.8%
Other anti-infective 23 8.0% 5 4.9% 18 9.0%
Electrolyte/vitamin 40 13.0% 13 12.7% 27 13.6%
Other 22 7.0% 3 2.9% 19 9.5%
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was located below the pump (4 in medical–surgical and 1 in 
critical care). Data show that none of the observations for 
the primary infusion setup were compliant with the head-
height differential system setup requirements of 20 inches 
between the pump and the primary IV head height.
Aim 2
What is the adherence with the 9.5-inch secondary 
head-height requirement with the head-height differ-
ential system during actual clinical use? Tables 4 and 5 
summarize the total and clinical unit-specific data on 
secondary head-height differentials. Overall, 16% (N = 
17/102) of the secondary head-height differentials were 
found to be <9.5 inches, with only minor differences 
between medical–surgical and critical care. Of the 17 
secondary infusions that did not meet the recommended 
head-height differential, 2 infusions in medical–surgical 
were found to have a head-height differential of 0 inches, 
whereas the remaining heights were between 7 and 9 
inches (Table 6).
Aim 3
Is there a difference in secondary medication administra-
tion delay between the 2 IV smart pump types during actual 
clinical use?
Back-check Valve
For the head-height differential system, it was found that 
100% of the primary lines did contain a back-check valve. 
For the cassette system, there is no need for a back-check 
valve because the cassette prevents backflow.
Roller Clamp
For the head-height differential system, 1 clamp (1% of 
observations) on the secondary line was found in the closed 
position, resulting in an omitted secondary medication dose 
that was not detected. For the cassette system, 2 clamps 
(1%) were found to be in the closed position on initiation 
of the secondary infusion. In both cases, the clinician was 
alerted by the alarm, and no medication delay occurred.
DISCUSSION
The findings from Aim 1, primary head-height compliance, 
should be of concern to all practicing clinicians in the acute 
care setting. There were no observations where the primary 
head-height requirements were met, and 5 of the primary 
infusion bags were found to be hanging below the pump. Since 
flow rate accuracy and delivery of primary and secondary 
infusions	 are	 dependent	 on	 adhering	 to	 the	manufacturers’	
recommendations for the system setup, the impact of these 
findings on the accuracy of medication delivery is unknown. 
In the busy setting of acute care, nurses are required to con-
tinually balance complex and ever-changing patients care 
requirements. Any time a technical versus a manual solution 
can be used to improve the safety and efficiency of patient 
care, it should be considered. Based on these findings, cassette 
IV infusion technology provides an example of a technical solu-
tion that can improve both the quality and process of care for 
secondary medication administration.
TABLE 2









Mean 5.8 5.1 6.5
Median 5.2 5.0 6.0
SD 4.9 5.0 4.9
Minimum –4.0 –3.5 –4.0
Maximum 16.0 15.0 16.0
TABLE 3








Yes 0 0% 0 0% 0 0%
No 102 100% 102 100% 102 100%
TABLE 4








 (N = 51)
Mean 12.3 12.5 12.2
Median 12.0 12.0 12.0
SD 3.6 4.0 3.1
Minimum 0.0 0.0 7.0
Maximum 21.0 21.0 20.0
TABLE 5









Yes 86 84% 45 88% 41 78%
No 16 16% 6 12% 11 22%
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For Aim 2, while the majority (84%) of secondary med-
ication infusion setups did meet the 9.5-inch head-height 
differential requirement, 16% did not, which is a consider-
able degree of error. The 2 observations of a 0-inch differ-
ential very likely led to delayed administration of the sec-
ondary medication, while the remaining inadequate head 
heights had variable and unknown impacts on flow rate. 
More recent 2017 BD/Alaris product recommendations do 
not specify 9.5 inches as the differential needed to achieve 
the hydrostatic pressure for secondary flow but alterna-
tively describe the secondary more generally as needing to 
be sufficiently higher.29 This open-ended recommendation 
may lead to further inconsistency at the bedside, since no 
clinical guidance is provided in those recommendations for 
any operational definition of what sufficient means.
These findings provide evidence that it is difficult, if not 
impossible in some situations, to comply with the recom-
mendations for head height during actual clinical use of 
head-height IV smart pump systems. Clinical realities, such 
as limitations on space at the bedside, the availability and 
type of IV poles, and head-height requirements that make 
it impossible for most nurses to reach the IV bags without 
standing on a stool, all contribute to the lack of compliance 
with recommended head-height differential system setup. 
To illustrate this point, Figure 2 shows the implications of 
TABLE 6
Head-Height Differentials for 
Nonadherent Secondary Infusions





these setup requirements from the perspective of a frontline 
nurse. The middle photo depicts the 9.5-inch secondary setup 
requirement. These recommendations require frontline nurs-
es to conform to physical setup requirements that are often 
not possible at the bedside, which likely accounts for the 0% 
compliance with primary head-height recommendations.
For Aim 3, we found a total of 3 closed clamps, 1 with 
the head-height differential system that resulted in a missed 
dose and 2 with the cassette system, both of which alarmed, 
alerted the clinician, and did not result in missed doses.
Based on what is known regarding medication admin-
istration error with secondary infusion, errors of varying 
severity are occurring during actual clinical use without 
detection.16,17 These likely include reduced flow accuracy of 
the secondary infusion due to inadequate hydrostatic pres-
sure, concurrent flow of primary and secondary infusions, 
backflow from the secondary into the primary due to back-
check valve failure, and, in this small sample, 1 documented 
occurrence of a missed dose due to a closed clamp. While 
data on the position of the pump relative to the patient 
were not collected in this study, anecdotal observations 
noted by the data collector found that the pumps were 
positioned in a variety of locations relative to the patient, 
including below the patient.
The impact on the delivery of antibiotics is concerning, 
because the majority of medications (72%) administered by 
secondary infusion were antibiotics (Table 1). When other 
anti-infectives are included, the total is 80%. Incomplete 
dosing of antibiotics not only decreases the therapeutic 
benefit to the patient but also contributes to antibiotic 
resistance due to the resultant subtherapeutic levels, which 
foster bacterial mutation.30 While appropriate and timely 
antibiotic administration as prescribed is always important, 
in certain clinical situations like sepsis, where every hour 
delay in antibiotic administration results in an 8% increase 
in mortality,19 it can literally make the difference between 
life and death.20,31,32
Figure 2 Using a commonly available intravenous pole and the 9.5-inch secondary hanger, if the recommendations for primary and secondary 
head heights are followed, it is not possible for this 5′5″ nurse to reach the secondary medication bag. Images used with permission from Melody 
Bennett, MN, RN.
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LIMITATIONS
This study was conducted in 2 hospitals that were chosen 
to be similar in bed size, urban location, patient acuity, and 
annual patient discharges. The findings from these 2 hospi-
tals are not necessarily representative of the practices in all 
US hospitals. The authors acknowledge that the study used 
a point-prevalence, convenience sample design, and obser-
vational approach with data collected over a 2-day period, 
so the findings should be interpreted in that context. As 
the study was primarily descriptive in nature, a larger-scale 
trial with multiple sites, additional IV smart pump types, 
different size hospitals, and a larger sample size is needed 
to more thoroughly describe IV smart pump medication 
administration practices in a way that is more generalizable. 
This is especially important to study the issue of medica-
tion	 delay.	 Even	 with	 these	 limitations,	 it	 is	 the	 authors’	
hope that this study provides an example of the type of 
practice-based research that can generate data from the 
point of care to support improvement in IV medication 
administration safety and inform future recommendations 
for implementation science.
CONCLUSION AND IMPLICATIONS FOR 
FUTURE RESEARCH
In addition to a larger-scale study, a knowledge assessment 
of direct care nurses on the topic is warranted. It is import-
ant to learn more about the overall knowledge level of 
these professionals concerning the technical requirements, 
limitations, and clinical effects of secondary medication 
administration and the potential for error. This information 
is important for the development and implementation of 
educational materials that may, at least in the short term, 
help improve the secondary medication administration 
process. However, even if frontline caregivers are provid-
ed with all the relevant knowledge, the current system 
requirements for flow rate accuracy using head-height 
differential systems are simply not possible to achieve con-
sistently at the point of care. There is a need for additional 
human-factors designed technology to replace manual 
processes to improve the process of care for nurses and the 
safety of care for patients.
Much more research is needed to understand the varia-
tions in flow rate accuracy under the conditions that actu-
ally exist in acute care, as reported data are generally lim-
ited to manufacturer recommendations and requirements. 
Because most IV smart pumps were developed before the 
current FDA requirements for human-factors safety testing, 
there is a lack of practice-based flow rate data to help guide 
clinical decision-making. ECRI, a noncommercial organi-
zation for health care technology assessment, regularly 
publishes IV infusion comparative effectiveness reports and 
issues recommendations. Their recent IV infusion report 
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